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Summary Lower pre-chemotherapy night time cortisol excretion predicted more severe cisplatin induced
nausea and vomiting in 42 ovarian cancer patients receiving ondansetron as a single antiemetic agent.
Dexamethasone administration added to the antiemetic effect of ondansetron principally in patients who had
low excretion of cortisol.
Corticosteroids as single antiemetic agents have a well
documented effect on mild to moderate chemotherapy
induced emesis (Cassileth et al., 1983). During highly
emetogenic chemotherapy, there is a synergistic antiemetic
effect of corticosteroids and metoclopramide or 5-hydroxy-
tryptamine (5-HT3) receptor antagonists (Kris et al., 1989;
Smith et al., 1991). Recently we reported that nausea during
chemotherapy with low emetic potential was inversely related
to urinary cortisol excretion (Fredikson et al., 1992). These
results suggested that cortisol, like exogenous corticosteroids,
exert an antiemetic action.
The aim of the present study was to relate endogenous
cortisol secretion to cisplatin induced nausea and vomiting.
Also, the potential interactions among cortisol, exogenous
corticosteroids and ondansetron were investigated. Patients
were double blinded and randomised to receive ondansetron
combined with dexamethasone or placebo. As in our
previous study (Fredrikson et al., 1992), night time urine was
collected to assay cortisol excretion.
Materials and methods
Patients
Forty-two consecutive patients receiving chemotherapy for
ovarian cancer at the Department of Gynecological On-
cology, Radiumhemmet, Karolinska Hospital participated.
The chemotherapy included either cisplatin (50 mg m-2) com-
bined with doxorubicin (50 mg m-2) during a single day
(n = 11) or doxorubicin (40 mgm2) and melphalan (0.4 mg
kg-') on day 1 and cisplatin (50 mg m-2) on day 2 (n = 31).
As antiemetic medication, patients received ondansetron
(8 mg, i.v. x 3, 30 min prior to, and 2 and 6 h after the start
of chemotherapy) and were randomised to combine ondan-
setron either with dexamethasone (20 mg, i.v. x 1) or placebo
given 6 h after the cisplatin infusion was started. Addi-
tionally, all patients received ondansetron (8 mg, p.o. x 3)
daily during 5 days after the chemotherapy. The mean age of
the patients was 53.6 years with a range of 39-74. The study
was approved by the local ethics committee and informed
consent was obtained.
Procedure
The urinary sample was collected from the time of voiding
before going to bed the night before the start of the second
chemotherapy course, until the time of rising next morning.
Urine was collected in a plastic container with sodiumdisulfit
as antioxidant. Volume and collection time were noted and
the specimens were stored at - 18'C until analysed for cor-
tisol by radioimmunoassay (kits from Farmos, Finland). Ex-
cretion rate was expressed in pmolmin-'.
Patients rated their nausea during the past 24 h at the
morning of the first and second day after the cisplatin
infusion by choosing one of four alternatives ranging from
none to severe nausea. At the first morning patients also used
a 100 mm visual analog scale (VAS) to report the severity of
nausea. A zero score is anchored at the left end with 'no
nausea at all' and a maximum score of 100 'worst possible
nausea'. Emetic episodes (vomiting or retching) were
recorded by patients during both days.
In the statistical analyses patients responding with 'no' or
'mild' nausea were treated as one group and those respon-
ding 'moderate' or 'severe' nausea formed the other group.
Regarding the emetic episodes, patients with complete or
major response (<2 emetic episodes) formed one group
whereas minor response and failure (>3 emetic episodes)
formed the other group. A median split approach was used
to form groups with relatively high and low cortisol excre-
tion. Relative risk was used to describe the association
between urinary cortisol levels and nausea and vomiting.
Relative risk was calculated as the ratio between the propor-
tions of patients with moderate or severe nausea, or >3
emetic episodes in respective groups of interest. Calculation
of 95% confidence intervals was performed as described by
Greenland & Robins (1985). Student's t-test with one-tailed
P-values was used to analyse VAS-ratings of nausea and the
total number of emetic episodes.
Results
The median used to form groups high and low in cortisol
excretion was 23.2pmolmin-'. The high and low excretion
group had a mean (standard error of the mean) of 38.7 (2.5)
and 16.5 (0.9) pmol min-', respectively. The groups did not
differ concerning the percentage of 1- vs 2-day chemotherapy
course (chi2 = 0.12, P = 0.73). The mean cortisol excretion in
patients receiving dexamethasone was 28.8 pmol min-' and
in those receiving placebo 25.8 pmol min-' (t (40) = 0.68,
P = 0.50). Evaluating the importance of age for the studied
variables, patients were categorised by their median age (50
years). No significant association was found between patient's
age, cortisol excretion, nausea intensity or emetic episodes (t
(40)<1.12, chi2 (1)<0.54, P's>0.26).
Among patients receiving ondansetron and placebo, those
with relatively lower cortisol excretion had more emetic
episodes on the chemotherapy day than those with higher
excretion (t (15) = 2.69, P= 0.009 (Figure 1). They also
tended to experience more intense nausea (t (15) = 1.67,
P = 0.058) (Figure 2). In patients with low cortisol levels, the
number of emetic episodes was significantly lowered after the
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Figure I Mean number of emetic episodes on the chemotherapy
day as a function of night time cortisol excretion in patients
receiving dexamethasone or placebo in addition to ondansetron.
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Figure 2 Mean nausea intensity (value on a 100 mm visual
analog scale) on the chemotherapy day as a function of night
time cortisol excretion in patients receiving dexamethasone or
placebo in addition to ondansetron.
Table I Relative risks (with 95% confidence intervals) of three or more emetic
episodes and moderate or severe nausea on the chemotherapy day and the day after
chemotherapy in patients with low compared to high night time cortisol excretion.
Separate analyses forpatients receiving ondansetron and placebo and thosereceiving
ondansetron and dexamethasone are presented
In patients receiv,ing
Ondansetron Ondansetron
andplacebo and dlexamethasone
Chemotherapy, day
Relative risk of emetic episodes 1.9 (0.8-4.6) 1.0 (0.3-3.4)
for low vs high cortisol excretion
Relative risk of nausea 1.8 (0.9 3.3) 1.1 (0.4-2.6)
for low v,s high cortisol excretion
Day afier chemotherapy
Relative risk of emetic episodes 1.9 (0.4-20.0) 0.6 (0.2-2.0)
for low vs high cortisol excretion
Relative risk of nausea 3.2 (1.0- 10.4) 0.6 (0.3 1.6)
for low vs high cortisol excretion
administration of dexamethasone (t (17) = 2.24, P = 0.019)
(Figure 1), while in patients with high cortisol excretion
vomiting was not affected by dexamethasone treatment (t
(19) = 0.12, P = 0.45) (Figure 1). All the other differences in
Figures 1 and 2 are statistically non-significant (P's>0.12).
The same effect of endogenous cortisol levels was apparent
when the relative risk of severe nausea and vomiting was
calculated as shown in Table 1, upper part. The day after
chemotherapy the association between cortisol excretion and
nausea and severe vomiting was stronger, although the
confidence intervals for the relative risk of severe emesis were
very wide (Table I, lower part).
Discussion
Lower pre-chemotherapy night time cortisol excretion
predicted more severe cisplatin induced nausea and vomiting
in patients receiving ondansetron as antiemetic treatment.
The association was virtually absent in those receiving
ondansetron combined with dexamethasone. This inverse
relation between cortisol excretion and nausea severity is
consistent with our previous study in patients receiving low
emetogenic chemotherapy (Fredrikson et al., 1992). In the
present study administration of exogenous corticosteroids
added to the antiemetic effect of ondansetron primarily in
patients with relatively lower endogenous cortisol secretion.
The results suggest that endogenous cortisol exerts an
antiemetic effect comparable to that obtained by administra-
tion of exogenous corticosteroids. When an antiemetic action
of dexamethasone is established at a certain dose, escalating
doses only carry little additional benefit (Coleman et al.,
1991). Our results mimic these findings indicating that sub-
jects with sufficiently high endogenous cortisol levels gain
little, if any, on exogenous corticosteroids as antiemetic
medication.
All the patients participating in the study had a diagnosis
of ovarian cancer and the differences in their chemotherapy
regimen (1- or 2-day mode) were not related to nausea and
vomiting. Patient's age, which in some studies has predicted
nausea, was not associated with nausea among our subjects
and accordingly did not affect the obtained results. The
assessment of nausea and vomiting was accomplished in a
'doubleblind' fashion without any knowledge about patients'
cortisol levels or whether exogenous corticosteroids were
administered. Thus, the association between cortisol excre-
tion and individual differences in nausea and vomiting is
unlikely to reflect confounding caused by these factors.
The mechanism of action whereby corticosteroids affect
nausea is by and large unknown although several central and
peripheral pathways have been suggested (Fredrikson et al.,
1992; Sagar, 1991). The exposure of emetogenic trigger sites
to toxic stimuli may be reduced by modified capillary
permeability of the CNS (Livera et al., 1985). Corticosteroids
may reduce levels of 5-HT in neural tissue by depleting its
precursor, tryptofan (Young, 1981). The anti-inflammatory
properties of cortisol may act to prevent the release of
serotonin in the gut or prevent activation of 5-HT receptors
in the gastrointestinal system (Fredrikson et al., 1992). When
used as a complement to other classes of antiemetics, cor-114 T.J. HURSTI et al.
ticosteroids have also been suggested to potentiate the main
antiemetic effect by sensitising the pharmacological receptor
(Sagar, 1991). Our results suggest that endogenous cortisol,
too modifies the antiemetic effect. This could partly explain
the individual differences in response to antiemetic treatment,
as observed in this and other studies.
We are indebted to Dr Gary Morrow for comments on a previous
draft and to Kristina Bertilsson, RN, for technical assistance. This
study was supported by grants from the Swedish Cancer Society and
the King Gustav V's Jubilee Foundation.
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